

Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)	Chronic hepatitis C

Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 60 mg + 400 mg	Chronic hepatitis C

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 20 mg granules Oral > Solid > tablet: 100 mg + 40 mg	Chronic hepatitis C

Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg	Chronic hepatitis C

Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg; 400 mg	Chronic hepatitis C

Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg	Chronic hepatitis C